Form 483

Tubilux Pharma Spa Form 483, 2018-04-06

FDA issued a Form 483 to Tubilux Pharma Spa on 2018-04-06 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

Tubilux Pharma Spa · Pomezia, Italy · Issued April 6, 2018

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Apr 2018
21 CFR 211.166(a)

Lack of written stability program

Cited by Joey V Quitania, David J Gomes

6 Apr 2018
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Joey V Quitania, David J Gomes

6 Apr 2018
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Joey V Quitania, David J Gomes

Inspected site

TPTubilux Pharma SpaPomezia, Italy

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 3 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere